The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Between 2026 And 2030?
The artificial intelligence (AI)-powered rare disease diagnosis market size has expanded significantly in recent years. This market is projected to increase from $1.99 billion in 2025 to $2.56 billion in 2026, at a compound annual growth rate (CAGR) of 28.9%. The historical expansion can be attributed to factors such as the growing diagnostic complexities for rare conditions, the wider availability of genetic testing, increased funding for rare disease research, the expanding application of data analytics in healthcare, and the early integration of AI-powered diagnostic tools.
The artificial intelligence (AI)-powered rare disease diagnosis market size is projected to experience substantial growth in the upcoming years. This market is set to achieve a valuation of $7.08 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. The expansion during this projection period is primarily driven by an increasing emphasis on personalized medicine, the greater implementation of AI-assisted clinical decision support systems, the broadening integration of genomic sequencing, rising investments in rare disease screening programs, and an augmented need for diagnostic efficiency. Prominent trends within the forecast timeframe include the expanding application of AI for pattern recognition in rare diseases, the greater uptake of genomic data analytics platforms, enhanced fusion of multi-modal patient data, the proliferation of cloud-based diagnostic solutions, and a strengthened focus on early and accurate diagnosis.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Major Drivers Are Influencing The Expansion Of The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
The increasing occurrence of autoimmune disorders is anticipated to stimulate the expansion of the artificial intelligence (AI)-powered rare disease diagnosis market moving forward. Autoimmune disorders are conditions in which the immune system mistakenly attacks the body’s own healthy cells and tissues, leading to inflammation and damage. The widespread nature of autoimmune disorders is attributed to a growing number of individuals experiencing immune system dysfunctions, which creates a higher demand for early diagnosis, advanced treatments, and continuous monitoring to effectively manage symptoms. Artificial intelligence (AI)-powered rare disease diagnosis assists in managing autoimmune disorders by quickly identifying complex conditions, supporting personalized treatment decisions, and improving overall diagnostic accuracy. For instance, in January 2025, the Mayo Clinic, a US-based nonprofit academic medical center, reported an estimate of about 15 million people having one or more of 105 autoimmune diseases. Therefore, the rising prevalence of autoimmune disorders is a key factor driving the growth of the artificial intelligence (AI)-powered rare disease diagnosis market.
What Segment Categories Shape The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Segment Landscape?
The artificial intelligence (AI)-powered rare disease diagnosis market covered in this report is segmented –
1) By Component: Software, Hardware, Services
2) By Technology: Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Other Technologies
3) By Deployment Mode: Cloud-Based, On-Premises
4) By Diagnosis Type: Genetic Disorders, Autoimmune Disorders, Metabolic Disorders, Infectious Diseases, Other Diagnosis Types
5) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users
Subsegments:
1) By Software: Clinical Decision Support, Data Analytics Platforms, Genomic Interpretation Tools, Machine Learning Algorithms, Diagnostic Reporting Software
2) By Hardware: Sequencing Instruments, Imaging Devices, Laboratory Equipment, Computational Servers, Diagnostic Sensors
3) By Services: Consulting Services, Implementation And Integration, Training And Support, Data Management Services, Maintenance And Upgrades
Which Trends Are Shaping The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
Companies operating in the artificial intelligence (AI)-powered rare disease diagnosis market are focusing on developing innovative technologies, such as unified genomic diagnostics solutions, to enhance diagnostic precision, reduce turnaround times, and provide more comprehensive insights into complex genetic disorders. A unified genomic diagnostics solution is an integrated system that combines whole-genome sequencing and artificial intelligence (AI)-driven analysis to deliver complete genetic insights. For instance, in October 2023, Oxford Nanopore Technologies plc, a UK-based biotechnology company, and Fabric Genomics Inc., a US-based artificial intelligence (AI)-based company, launched an integrated whole-genome sequencing solution aimed at accelerating rare disease diagnosis by combining rapid sequencing with AI-driven variant interpretation for more accurate and actionable clinical insights. This launch integrates real-time nanopore sequencing with artificial intelligence (AI)-powered genomic analysis to quickly identify rare genetic variants. It provides comprehensive, actionable insights to clinicians, thereby improving diagnostic speed and accuracy for pediatric care.
Who Are The Companies Operating Across The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Value Chain?
Major companies operating in the artificial intelligence (AI)-powered rare disease diagnosis market are Ambry Genetics Corporation, MedGenome Inc., Sophia Genetics SA, Variantyx Inc., Atropos Health Inc., Congenica Ltd., Saventic Care Sp. z o.o., Rapid Innovation LLC, Centogene N.V., Impilo AB, ThinkGenetic Inc., ClairLabs Ltd., 3billion Inc., OpenEvidence Inc., GenomeUp S.R.L., Mendel.ai Inc., RareSum GmbH, DeepRare AI Solutions, Zebra-Llama Project
Get The Full Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Report:
Which Region Is The Top Contributor To The Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market By Share?
North America was the largest region in the artificial intelligence (AI)-powered rare disease diagnosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered rare disease diagnosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market 2026, By The Business Research Company
Artificial Intelligence In Cancer Diagnostics Market Report 2026
Artificial Intelligence In The Diagnostic Market Report 2026
Ai In Medical Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model